J&J Wins Latest Talc Lawsuit as Scientific Debate Over Ovarian Cancer Link Continues

New York, June 5, 2026 — A Los Angeles County Superior Court jury sided with Johnson & Johnson (J&J) on Friday, dismissing a high-profile lawsuit filed by the families of three women who claimed the company’s talc-based products caused their fatal ovarian cancers. The defense verdict marks another significant win for the healthcare giant in its multi-year legal battle against tens of thousands of similar consumer complaints. However, the legal victory comes at a time when the broader scientific and medical communities remain deeply divided over whether perineal (genital) use of cosmetic talcum powder poses a genuine oncological risk.

The verdict concludes a trial brought by the grieving families of Mary Owens, Bonnie Tienken, and Geneva Williams, all of whom used Johnson’s Baby Powder for decades before developing ovarian cancer. While the jury ultimately found that J&J was not negligent in its manufacturing or marketing practices, the outcome highlights a stark disconnect between the clear-cut resolutions of the courtroom and the complex, muddy realities of public health science.

Legal Volatility: A Tale of Disparate Verdicts

Friday’s decision provides major momentum for J&J, which is currently navigating a sea of more than 67,000 pending talc-related lawsuits nationwide. Erik Haas, J&J’s vice president of litigation, strongly praised the verdict, reiterating the corporate stance that plaintiffs’ claims are driven by “junk science” rather than rigorous empirical data. Just last week, J&J secured a similar defense win in an Oklahoma state court, maintaining what it calls a strong legal track record—securing favorable outcomes in 16 of its last 17 ovarian cancer cases tried to completion.

Yet, this string of corporate victories stands in sharp contrast to several staggering losses that keep the litigation alive. Most recently, in December 2025, a California jury ordered J&J to pay a combined $40 million to two plaintiffs, Monica Kent and Deborah Schultz, after concluding their cancers were directly linked to forty years of baby powder use. Most notably, a landmark 2018 ruling forced the company to award $4.69 billion to 22 women, though that figure was later reduced on appeal.

While J&J has successfully settled the vast majority of its lawsuits involving mesothelioma—a rare cancer firmly tied to inhalation of asbestos fibers—the ovarian cancer claims have proven far more legally volatile and scientifically challenging to resolve.

Deciphering the Science: Why Studies Clash

To understand why juries arrive at such wildly differing conclusions, one must look at the underlying epidemiological data. The medical literature on cosmetic talc is essentially a tale of two study designs, each yielding conflicting insights.

The Case for Increased Risk

Many retrospective case-control studies—which look backward at patients who already have a diagnosis—suggest a distinct statistical correlation. A comprehensive 2024 systematic review published in the European Journal of Cancer Prevention found that perineal use of commercial talcum powder increases ovarian cancer risk by odds ratios up to 1.5.

Furthermore, a June 2024 study led by Dr. Katie O’Brien at the National Institute of Environmental Health Sciences (NIEHS) utilized detailed data from the “Sister Study” to map lifetime exposure. The findings revealed that:

• Any genital talc use was associated with a 31% increased risk of developing ovarian cancer compared to non-users.

• Frequent and long-term users faced the highest odds, with those exceeding 3,600 lifetime applications showing a 42% increased risk.

Biomedical researchers have hypothesized that talc particles, when applied to the female genitalia, can migrate upward through the reproductive tract, inducing chronic inflammation in the fallopian tubes or ovaries. Recent laboratory work published in Critical Reviews in Toxicology suggests talc can induce cellular oxidative stress, mimicking certain functional hallmarks of early-stage cancer progression.

The Case for No Link

Conversely, prospective cohort studies—which follow healthy individuals forward through time—generally show no definitive link. The absolute gold standard in this category is a massive 2020 pooling analysis published in JAMA. Led by the National Institutes of Health, researchers tracked 252,745 women for an average of 11.2 years.

The JAMA study found:

• An 8% overall increased risk for women using powder, a figure that failed to reach statistical significance.

• A tiny estimated absolute risk increase of just 0.09% by age 70.

• A mild 13% increased risk specifically among women with intact reproductive tracts, though the absolute risk remained marginal.

“No study can ever say definitively what the cause of cancer is,” noted Dr. Sarah Gossett, a gynecologic oncologist who was not involved in the JAMA research. “But this study at least shows there’s not a substantial, alarming increase in ovarian cancer risk for the average consumer.”

Public Health Classifications and Conflicting Realities

Because the empirical data remains contradictory, major health organizations have classified the risk with a high degree of nuance:

“The fact remains that the science is inconclusive about increased risk of ovarian cancer to women using talcum powder,” emphasized Audra Moran, President and CEO of the Ovarian Cancer Research Alliance (OCRA).

This scientific gridlock stems from inherent research limitations. Retrospective studies often suffer from recall bias, where women diagnosed with cancer are much more likely to remember using talc than healthy individuals. On the flip side, because ovarian cancer is relatively rare—affecting roughly 1.3% of women over a lifetime—even a prospective study tracking a quarter-million women may lack the statistical power necessary to capture a truly minute risk increase. Furthermore, while natural talc deposits can sometimes sit adjacent to underground asbestos veins, cosmetic-grade talc has been strictly required by law to be entirely asbestos-free since 1976.

Consumer Guidance: Navigating the Aisles

For health-conscious consumers and healthcare providers attempting to synthesize this barrage of legal headlines and scientific data, the practical takeaway focuses heavily on risk mitigation and absolute vs. relative risk.

It is crucial to understand that even in studies indicating a higher relative risk, the absolute risk of developing ovarian cancer from talc use remains very small. Millions of women used talcum powder daily for generations without ever developing oncological complications.

Furthermore, the consumer marketplace has already shifted dramatically. In 2020, J&J permanently discontinued sales of its talc-based baby powder in the United States and Canada, transitioning its global portfolio entirely to cornstarch-based alternatives, which do not carry the same respiratory or reproductive health concerns.

The American Cancer Society currently advises that anyone concerned about a potential link simply limit or entirely avoid using products that contain natural talcum powder. For individuals with an elevated baseline risk—such as a strong family history of ovarian or breast cancer, or known BRCA gene mutations—choosing cornstarch alternatives or avoiding perineal powders altogether is a prudent, low-effort preventive measure.

With a second major bellwether trial scheduled to begin in January 2026 before Judge Theresa Traber in Los Angeles, the courtroom battles will undoubtedly continue. But until the molecular mechanisms of talc-induced tissue irritation are definitively mapped, the scientific jury will remain out long after the legal juries have gone home.

Medical Disclaimer

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Reuters. “J&J beats lawsuit alleging that talc caused three women’s cancer.” Reported June 5, 2026.